Structure

InChI Key CFCMMYICHMLDCC-RMIBZTJPSA-N
Smile CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O.O=S(=O)(O)O
InChI
InChI=1S/C21H39N7O12.H2O4S/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;1-5(2,3)4/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);(H2,1,2,3,4)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C42H84N14O36S3
Molecular Weight 1457.4
AlogP -8.16
Hydrogen Bond Acceptor 15.0
Hydrogen Bond Donor 12.0
Number of Rotational Bond 9.0
Polar Surface Area 336.43
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 40.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Bacterial 70S ribosome inhibitor FDA PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference

Related Entries

Scaffolds

Parent

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Immune system disorders
52.32
Skin and subcutaneous tissue disorders
10.6
General disorders and administration site conditions
8.61
Vascular disorders
5.3
Blood and lymphatic system disorders
3.97
Gastrointestinal disorders
3.97
Nervous system disorders
3.97
Injury, poisoning and procedural complications
2.65
Musculoskeletal and connective tissue disorders
2.65
Respiratory, thoracic and mediastinal disorders
2.65

Cross References

Resources Reference
ChEBI 32158
ChEMBL CHEMBL3184791
EPA CompTox DTXSID9026053
FDA SRS CW25IKJ202
PubChem 19648
SureChEMBL SCHEMBL4960167